

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Katherine Meyer Siegler
Application No: 10/644,797
Filed: December 17, 2003
For: SERUM MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AS MARKER FOR
PROSTATE CANCER

Group Art Unit: 1643
Confirmation No. 7390
Examiner: Stephen L. Rawlings

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicant(s) wish to make of record the references listed on the attached form PTO/SB/08 (substitute for PTO-1449). Copies of the listed references are attached, where required, as are either statements of relevancy (☐ attached) or any readily available English translations of pertinent portions of any non-English language references.

- ☒ This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination (RCE). No certification or fee is required.
- ☐ This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement. No fee is required.
- ☐ No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement. No fee is required.
- ☐ A check in the amount of \$180.00 is enclosed under 37 CFR §1.17(p).
- ☐ This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. A check in the amount of \$180.00 is enclosed under 37 CFR §1.17(p).
- ☐ Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

Blank Rome LLP
600 New Hampshire Avenue, N.W.
Washington, DC 20037
Tel: (202) 772-5800
Fax (202) 572-8398
Customer No.: 27557
Date: May 21, 2007

Respectfully submitted,

Charles R. Wolfe, Jr.
Attorney of Record
Registration No. 28,680



TO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/644,797
Filing Date	December 17, 2003
First Named Inventor	Katherine Meyer Siegler
Art Unit	1643
Examiner Name	Stephen L. Rawlings
Attorney Docket Number	111828-00109

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MICHAEL, Anja et al, "Serum Macrophage Migration Inhibitory Factor Is Not Elevated in Patients with Prostate Cancer". Cancer Epidemiology, Biomarkers & Prevention, Vol. 13, pages 328-329, February 2004.	
		LI, Haojie et al, "Prediagnostic Plasma Vascular Endothelial Growth Factor Levels and Risk of Prostate Cancer". Cancer Epidemiology, Biomarkers & Prevention, June 2005 Vol. 14(6), pages 1557-1561.	
		YOUSEF, G. M. et al, "Differential Expression of the Human Kallikrein Gene 14 (KLK14) in Normal and Cancerous Prostatic Issues". Prostate, September 1, 2003 Vol. 56(4), pages 287-292.	
		BORGONO, Carla A. "Human Kallikrein 14: A New Potential Biomarker for Ovarian and Breast Cancer". Cancer Research Vol. 63, December 15, 2003, pages 9032-9041.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BR 06/04

111828.00109/35793757v.1